UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    Form 8-K

                                 Current Report
     Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported): March 24, 2005



                           DRAGON PHARMACEUTICAL INC.
                           --------------------------
             (Exact name of registrant as specified in its charter)


           Florida                        0-27937                65-0142474
           -------                        -------                ----------
(State or Other Jurisdiction of    (Commission File Number)     (IRS Employer
          Incorporation)                                     Identification No.)


       1055 Hastings Street, Suite 1900
         Vancouver, British Columbia                    V6E 2E9
         ----------------------------                   -------
    (Address of Principal Executive Offices)           (Zip Code)


                                 (604) 669-8817
                                 --------------
              (Registrant's telephone number, including area code)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)

[ ]  Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))

<PAGE>


Section 2 - Financial Information
---------------------------------

Item 2.02  Results of Operations and Financial Condition

     Dragon  Pharmaceutical  Inc.  announced  its  results  for the  year  ended
December 31, 2004 on the attached press release.

Item 2.05  Cost Associated with Exit or Disposal Activities

     At the  Board of  Directors'  meeting  held on March  24,  2005,  the Board
decided to relocate  its  biotech  production  facility  at  Nanjing,  China and
construct a new facility in Datong,  China.  It is anticipated  that the Nanjing
production  facility  will be closed in August  2005.  In  connection  with this
decision,  the  Company has written off and  accelerated  the  depreciation  and
amortization  of certain  assets related to the Nanjing  production  facility of
$938,000  during  the  last  quarter  of 2004.  The  Company  believes  that the
estimated  cost to build the  biotech  production  facility  in  Datong  will be
approximately $2 million.

Section 9 - Financial Statements and Exhibits
---------------------------------------------

Item 9.01  Financial Statements and Exhibits

         Exhibit No.                Exhibit Description
         -----------                -------------------

         99                         Press release announcing year end results



<PAGE>


                                    SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                           DRAGON PHARMACEUTICAL INC.,
                                           a Florida Corporation


Dated:  March 29, 2005                     /s/ Maggie Deng
                                           -------------------------------------
                                           Maggie Deng
                                           Chief Operating Officer



<PAGE>


                                  EXHIBIT INDEX
                                  -------------


         Exhibit No.           Description
         -----------           -----------

              99               Press release dated March 30, 2005 titled "Dragon
                               Announces 2004 Year End Results"
[{"type": "8-K", "sequence": "1", "filename": "for032405.txt", "description": "FOR EVENT 032405", "secsgml_size_bytes": 4264}]
{"company-data": {"conformed-name": "DRAGON PHARMACEUTICAL INC", "cik": "0001075206", "assigned-sic": "2834", "irs-number": "650142474", "state-of-incorporation": "FL", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-27937", "film-number": "05715412"}, "business-address": {"street1": "543 GRANVILLE STREET SUITE 1200", "city": "VANCOUVER BC V6C 1X8", "state": "A1", "zip": "V6E 2E9", "phone": "6046698817"}, "mail-address": {"street1": "543 GRANVILLE STREET SUITE 1200", "street2": "VANCOUVER BRITISH COLUMBIA CANADA V6C1X", "city": "VANCOUVER BRITISH CO", "state": "A1", "zip": "V6E 2E9"}, "former-company": {"former-conformed-name": "DRAGON PHARMACEUTICALS INC", "date-changed": "19991022"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    Form 8-K

                                 Current Report
     Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported): March 24, 2005

                           DRAGON PHARMACEUTICAL INC.
                           --------------------------
             (Exact name of registrant as specified in its charter)

           Florida                        0-27937                65-0142474
           -------                        -------                ----------
(State or Other Jurisdiction of    (Commission File Number)     (IRS Employer
          Incorporation)                                     Identification No.)

       1055 Hastings Street, Suite 1900
         Vancouver, British Columbia                    V6E 2E9
         ----------------------------                   -------
    (Address of Principal Executive Offices)           (Zip Code)

                                 (604) 669-8817
                                 --------------
              (Registrant's telephone number, including area code)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)

[ ]  Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))
Section 2 - Financial Information
---------------------------------

Item 2.02  Results of Operations and Financial Condition

     Dragon  Pharmaceutical  Inc.  announced  its  results  for the  year  ended
December 31, 2004 on the attached press release.

Item 2.05  Cost Associated with Exit or Disposal Activities

     At the  Board of  Directors'  meeting  held on March  24,  2005,  the Board
decided to relocate  its  biotech  production  facility  at  Nanjing,  China and
construct a new facility in Datong,  China.  It is anticipated  that the Nanjing
production  facility  will be closed in August  2005.  In  connection  with this
decision,  the  Company has written off and  accelerated  the  depreciation  and
amortization  of certain  assets related to the Nanjing  production  facility of
$938,000  during  the  last  quarter  of 2004.  The  Company  believes  that the
estimated  cost to build the  biotech  production  facility  in  Datong  will be
approximately $2 million.

Section 9 - Financial Statements and Exhibits
---------------------------------------------

Item 9.01  Financial Statements and Exhibits

         Exhibit No.                Exhibit Description
         -----------                -------------------

         99                         Press release announcing year end results
SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                           DRAGON PHARMACEUTICAL INC.,
                                           a Florida Corporation

Dated:  March 29, 2005                     /s/ Maggie Deng
                                           -------------------------------------
                                           Maggie Deng
                                           Chief Operating Officer
EXHIBIT INDEX
                                  -------------

         Exhibit No.           Description
         -----------           -----------

              99               Press release dated March 30, 2005 titled "Dragon
                               Announces 2004 Year End Results"